Cost of shingles: Population based burden of disease analysis of herpes zoster and postherpetic neuralgia

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Friesen, Kevin J ^a   Chateau, Dan ^a   Falk, Jamie ^a   Alessi Severini, Silvia ^a   Bugden, Shawn ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Administrative data; Burden; Economics; Epidemiology; Herpes zoster; Postherpetic neuralgia

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HERPES ZOSTER; HOSPITALIZATION COST; HUMAN; INCIDENCE; INFECTION RATE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MEDICAL CARE; OBSERVATIONAL STUDY; POPULATION RESEARCH; POSTHERPETIC NEURALGIA; PRESCRIPTION; ADULT; AGED; COST; ECONOMICS; FEMALE; HOSPITALIZATION; MALE; MANITOBA; MIDDLE AGED; NEURALGIA, POSTHERPETIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; VARICELLA ZOSTER VIRUS;

ADULT; AGED; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MANITOBA; MIDDLE AGED; NEURALGIA, POSTHERPETIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 85010382960     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2185-3     Document Type: Article

References (44)

1. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
2. Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain. 2008;9(1 Suppl 1):S3-9.
3. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340-6.
4. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48 Suppl 1:S2-7.
5. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26(3):675-97.
6. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 Suppl 1:S1-S26.
7. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305-14.
8. Fairley CK, Miller E. Varicella-zoster virus epidemiology--a changing scene? J Infect Dis. 1996;174 Suppl 3:S314-9.
9. Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccin. 2015;3(4):109-20.
10. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125(3):651-69.
11. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125-32.
12. Ono F, Yasumoto S, Furumura M, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 2012;39(11):902-8.
13. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
14. Ultsch B, Köster I, Reinhold T, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14(6):1015-26.
15. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38-47.
16. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197 Suppl 2:S228-36.
17. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of herpes zoster and its complications. J Infect. 2013;67(5):463-9.
18. Cebrián-Cuenca AM, Díez-Domingo J, San-Martín-Rodríguez M, Puig-Barberá J, Navarro-Pérez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis. 2011;11(1):302.
19. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23-24):3076-90.
20. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
21. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian pain society. Pain Res Manag. 2014;19(6):328-35.
22. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320-8.
23. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.
24. Drug Products Database. Health Canada website. http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. Accessed 9 Jan 2017.
25. Bilcke J, Ogunjimi B, Marais C, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096-109.
26. Blein C, Gavazzi G, Paccalin M, Baptiste C, Berrut G, Vainchtock A. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France. BMC Infect Dis. 2015;15(1):350.
27. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11(1):173.
28. Lionis CD, Vardavas CI, Symvoulakis EK, et al. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece. BMC Fam Pract. 2011;12(1):136.
29. Di Legami V, Gianino MM, Atti MCD, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25(43):7598-604.
30. Roos LL, Brownell M, Lix L, Roos NP, Walld R, Macwilliam L. From health research to social research: privacy, methods, approaches. Soc Sci Med. 2008;66:117-29.
31. Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public health research. Annu Rev Public Health. 2011;32:91-108.
32. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146-53.
33. Friesen KJ, Falk J, Alessi-severini S, Chateau D, Bugden S. Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia. J Pain Res. 2016;9:543-50.
34. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20(19-20):2500-7.
35. Solomon BA, Kaporis AG, Glass AT, Simon SI, Baldwin HE. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). J Am Acad Dermatol. 1998;38(5 Pt 1):763-5.
36. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360(9334):678-82.
37. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol Infect. 2012;140(6):1131-40.
38. Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect. 2002;44(4):211-9.
39. Russell ML, Dover DC, Simmonds KA, Svenson LW. Shingles in Alberta: before and after publicly funded varicella vaccination. Vaccine. 2014;32(47):6319-24.
40. Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011;29(47):8580-4.
41. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the united states, 1993-2006: Evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52(3):332-40.
42. Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS One. 2013;8(6):e66485.
43. Hilderman T, Katz A, Derksen S, et al. Manitoba immunization study. Winnipeg: Manitoba Centre for Health Policy; 2011. http://mchp-appserv.cpe.umanitoba.ca/reference/MB_Immunization_Report_WEB.pdf. Accessed 9 Jan 2017.
44. Government of Ontario. Ontario's Routine Immunization Schedule. http://www.health.gov.on.ca/en/public/programs/immunization/static/immunization_tool.html. Published 2016. Accessed 9 Jan 2017.